Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Panel Supports Class II For Wound Dressings, But More Controls When Antibiotics Are Added

Executive Summary

Most experts on US FDA’s General & Plastic Surgery Devices Advisory Committee recommended Sept. 21 that drug-containing wound dressings should be placed in the class II risk category, but some pushed for more oversight of products containing antibiotics, with some panelists recommending class III placement in those instances.

You may also be interested in...



FDA Panel To Consider Antimicrobial Effectiveness, Classifications Of Wound Dressings

In light of recent advances in wound-care technology, US FDA is asking its General and Plastic Surgery Devices advisory panel to discuss indications for use, and safety and effectiveness of the latest drug-containing wound dressings, as well as antimicrobial effectiveness of dressings, at a Sept. 20-21 meeting.

White House To Deliver 25 Million Face Masks To Low-Income Americans

The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.

HHS Secretary Nominee Becerra Commits To Telehealth Expansion, Procedure Price Transparency

At two recent confirmation hearings, HHS secretary nominee Xavier Becerra promised Senators he would help expand telehealth and procedure price transparency.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel